Abstract: The disclosure relates to accurately determining a DC energy signal, such as a DC current or DC voltage, which may be particularly useful when controlling a formation/testing current of a battery cell during formation and/or testing. In the battery formation/testing context, a current sensor is used to measure the current of the battery cell, which is used as a feedback signal for controlling the current to achieve a target current. The transfer function of the current sensor is used to improve the accuracy of the current measurement. Because the transfer function can be regularly determined during formation/testing, a lower-cost current sensor with relatively poor temperature coefficient may be used. Any change in the gain of the current sensor may be detected by the transfer function determination and corrected for. Therefore, high current control accuracy may be achieved at lower cost.

Abstract: Techniques for controlling a current of a battery cell during formation and/or testing are described. A current sensor is used to measure the current of the battery cell, which is used as a feedback signal for controlling the current to achieve a target current. The transfer function of the current sensor is used to improve the accuracy of the current measurement. Because the transfer function can be regularly determined during formation/testing, a lower-cost current sensor with relatively poor temperature coefficient may be used. Any change in the gain of the current sensor may be detected by the transfer function determination and corrected for. Therefore, high current control accuracy may be achieved at lower cost.

Abstract: The disclosure relates to accurately determining a DC energy signal, such as a DC current or DC voltage, which may be particularly useful when controlling a formation/testing current of a battery cell during formation and/or testing. In the battery formation/testing context, a current sensor is used to measure the current of the battery cell, which is used as a feedback signal for controlling the current to achieve a target current. The transfer function of the current sensor is used to improve the accuracy of the current measurement. Because the transfer function can be regularly determined during formation/testing, a lower-cost current sensor with relatively poor temperature coefficient may be used. Any change in the gain of the current sensor may be detected by the transfer function determination and corrected for. Therefore, high current control accuracy may be achieved at lower cost.

Abstract: Techniques for controlling a current of a battery cell during formation and/or testing are described. A current sensor is used to measure the current of the battery cell, which is used as a feedback signal for controlling the current to achieve a target current. The transfer function of the current sensor is used to improve the accuracy of the current measurement. Because the transfer function can be regularly determined during formation/testing, a lower-cost current sensor with relatively poor temperature coefficient may be used. Any change in the gain of the current sensor may be detected by the transfer function determination and corrected for. Therefore, high current control accuracy may be achieved at lower cost.

Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.

Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that have an up-regulation or a down-regulation in biomarker expression related to angiogenesis and vascular development. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Abstract: Techniques for improving noise performance while processing signals received from an electrochemical sensor are provided. In an example, an interface circuit can include a first amplifier configured to provide a voltage to a counter electrode of an electrochemical sensor, a second amplifier configured to receive sensor information from a working electrode of the electrochemical sensor and to provide concentration information using the sensor information. In certain examples, an input of the first amplifier can be directly coupled to an input of the second amplifier to attenuate noise, of either the first amplifier or the second amplifier, within the concentration information provided by the second amplifier.

Abstract: A photometry device can include a first to emit light to a target in response to a first current through the first LED, a second LED to emit light to the target in response to a second current through the second LED, and an inductor, coupled to the first and second LEDs, to store energy associated with at least one of the first and second currents.

Abstract: The present disclosure relates to a digital-to-analog converter (DAC) which includes a resistor string and a transfer function modification circuit. The transfer function modification circuit may be a calibration circuit for calibrating the DAC, The calibration circuit may include a plurality of current sources, which may be current DACs. Each of the current DACS inject current into, or drain current from, a respective node of the resistor string, in order to correct for voltage errors. The injected currents may be positive or negative, depending on the voltage error. The current DACs are controlled by trim codes, which are set dependent on the measured or simulated voltage errors for a given resistor string.

Abstract: A blood oxygenation sensor is provided comprising: a first current-powered light source to produce light having a first wavelength; a second current-powered light source to produce light having a second wavelength; a light sensor to produce a current signal having a magnitude that is indicative of intensity of light incident upon it; a current level driver circuit that includes a current source configured to couple the current source to alternatively provide current to one of the first current-powered light source and the second light current-powered light source; a processor configured to predict times of occurrence of one or more first time intervals in which arterial volume at a tissue site is at one of a maximum and a minimum; wherein the processor is configured to control the current source, to provide a first pattern of higher power-dissipation current pulses to the first and second current-powered light sources during the first time intervals, and to provide a second pattern of lower power-dissipation

Abstract: The present disclosure relates to a digital-to-analog converter (DAC) which includes a resistor string and a transfer function modification circuit. The transfer function modification circuit may be a calibration circuit for calibrating the DAC, The calibration circuit may include a plurality of current sources, which may be current DACs. Each of the current DACS inject current into, or drain current from, a respective node of the resistor string, in order to correct for voltage errors. The injected currents may be positive or negative, depending on the voltage error. The current DACs are controlled by trim codes, which are set dependent on the measured or simulated voltage errors for a given resistor string.

Abstract: An integrated circuit may include a semiconductor die having a trench formed in a surface of the semiconductor die. One or more circuit components may be formed on the surface of the semiconductor die. The trench can extend into the semiconductor die next to at least one circuit component. The trench may surround the circuit component partially or wholly. The trench may be filled with a material having a lower bulk modulus than the semiconductor die in which the trench is formed.

Abstract: An immune response subtype of cancer is associated with DNA damage which allows subjects to be stratified for particular therapies including immune therapies which may be combined with DNA damage therapeutics. A method for predicting responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint comprises determining the expression level of at least one gene selected from Table 2B, 2A or 1 in a sample from the subject. The determined expression level is used to predict responsiveness to an antagonist of an inhibitory immune checkpoint and/or an agonist of a stimulatory immune checkpoint.

Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Abstract: A photometry device can include a first LED to emit light to a target in response to a first current through the first LED, a second LED to emit light to the target in response to a second current through the second LED, and an inductor, coupled to the first and second LEDs, to store energy associated with at least one of the first and second currents.

Abstract: Techniques for improving noise performance while processing signals received from an electrochemical sensor are provided. In an example, an interface circuit can include a first amplifier configured to provide a voltage to a counter electrode of an electrochemical sensor, a second amplifier configured to receive sensor information from a working electrode of the electrochemical sensor and to provide concentration information using the sensor information. In certain examples, an input of the first amplifier can be directly coupled to an input of the second amplifier to attenuate noise, of either the first amplifier or the second amplifier, within the concentration information provided by the second amplifier.

Abstract: A semiconductor wafer is provided that includes at least two integrated circuits (ICs); a scribe line extends adjacent to the at least two ICs; and a first conductor extends within the scribe line and is electrically coupled to the at least two ICs.

Abstract: A blood oxygenation sensor is provided comprising: a first current-powered light source to produce light having a first wavelength; a second current-powered light source to produce light having a second wavelength; a light sensor to produce a current signal having a magnitude that is indicative of intensity of light incident upon it; a current level driver circuit that includes a current source configured to couple the current source to alternatively provide current to one of the first current-powered light source and the second light current-powered light source; a processor configured to predict times of occurrence of one or more first time intervals in which arterial volume at a tissue site is at one of a maximum and a minimum; wherein the processor is configured to control the current source, to provide a first pattern of higher power-dissipation current pulses to the first and second current-powered light sources during the first time intervals, and to provide a second pattern of lower power-dissipation